Dyne Therapeutics IncDYN
▲ ポジティブ技術関連度
Dyne is closer to market with its Duchenne muscular dystrophy treatment, with potential sales over $1B by 2030.
資産への影響 7
Biotech & Genomic Medicine
Dyne Therapeutics Inc
Recursion Pharmaceuticals IncRXRX
▼ ネガティブ競争技術関連度
Recursion is edged out as less preferred; product revenue years away despite recent proof of concept.
Takeda Pharmaceutical Co. Ltd.4502
言及
Merck & Company IncMRK
言及
Financials
Artificial Intelligence
Health Care
Sanofi SASAN
言及